Dover has entered into a definitive settlement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s merchandise will broaden Dover’s biopharma single-use manufacturing offering, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full 12 months 2022.
When the deal closes, Malema will become part of the PSG business unit inside Dover’s Pumps & Process Solutions phase.
“We see an amazing long-term growth alternative in the bioprocessing industry pushed by a strong and rising pipeline of effective novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra environment friendly single-use manufacturing processes helps a sturdy outlook for our choices of single-use parts to end-customers. We believe that pairing Malema’s expertise with our present portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our solutions to our prospects.”
“ pressure gauge are methodically building out our biopharma platform through proactive capacity additions, new product growth, and opportunistic acquisitions of highly-attractive niche element technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and additional strengthens our sensor portfolio with new proprietary technology. In addition to attractive biopharma purposes, we expect sturdy growth within the semiconductor area on the capability expansion and re-shoring tailwinds.”
Share